Date published: 2026-5-15

1-800-457-3801

SCBT Portrait Logo
Seach Input

C430048L16Rik Activators

C430003P19Rik Activators would be a term applied to molecules that specifically increase the activity of the protein encoded by the gene C430003P19Rik. The process of discovering and developing activators for a given protein typically involves a multifaceted approach, beginning with high-throughput screening (HTS). This process utilizes automated platforms to test a large library of chemical compounds for their ability to modulate protein function. In the case of C430003P19Rik, the HTS assays would be designed to detect an upregulation in the protein's activity. These assays often employ reporter systems that can include changes in fluorescence or luminescence to indicate protein activity. Such systems enable rapid quantification and identification of compounds that can enhance the activity of C430003P19Rik. Those molecules that show a significant and reproducible increase in activity are then selected for more thorough validation through secondary assays. These secondary assays are crucial as they confirm the activator's specific action on the protein, eliminating any false positives that may have arisen due to non-specific effects or artifacts of the initial screening process.

Once a compound has been validated as a genuine activator of C430003P19Rik, it then undergoes detailed mechanistic studies to understand the interaction with the target protein. Structural analysis techniques, such as X-ray crystallography or nuclear magnetic resonance spectroscopy (NMR), can provide high-resolution images of the protein in complex with the activator molecule, revealing how the activator binds to the protein and induces an increase in activity. This structural information is vital for understanding the precise molecular interactions that lead to activation. Additionally, biophysical assays like surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) are employed to measure the binding kinetics and affinity between the C430003P19Rik protein and its activators. These assays can reveal how quickly the activator binds to the protein and how strongly it is retained, which are both important parameters for understanding how the activator functions at a molecular level. What follows is an iterative process of structure-activity relationship (SAR) studies, where chemists synthesize derivatives of the activator molecules to fine-tune their properties.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX is a non-specific inhibitor of phosphodiesterases, enzymes responsible for breaking down cAMP. By preventing cAMP degradation, IBMX can sustain the activation of cAMP-dependent pathways, potentially enhancing the activity of C430048L16Rik if it's modulated by such pathways.

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA is an activator of protein kinase C (PKC). If C430048L16Rik activity is influenced by PKC-mediated signaling, PMA would enhance C430048L16Rik by activating PKC, which could phosphorylate substrates that regulate C430048L16Rik activity.

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$78.00
$270.00
80
(4)

Ionomycin is a calcium ionophore that increases intracellular calcium levels. Calcium signaling is crucial for numerous cellular processes, and if C430048L16Rik is affected by calcium-dependent mechanisms, ionomycin could enhance its activity by modulating these pathways.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

Thapsigargin is an inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels. Enhanced calcium signaling could indirectly activate C430048L16Rik if it is regulated by calcium-dependent pathways.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 is a calcium ionophore similar to ionomycin and can elevate intracellular calcium concentrations. This increase in calcium can enhance C430048L16Rik activity through the activation of calcium-sensitive signaling cascades.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

EGCG is a polyphenol found in green tea with kinase inhibitory activity. If C430048L16Rik is negatively regulated by specific kinases, EGCG could indirectly enhance C430048L16Rik activity by inhibiting those kinases.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

Genistein is a tyrosine kinase inhibitor. By inhibiting these kinases, Genistein can shift signaling pathways to reduce competition and enhance the activity of C430048L16Rik if it is regulated in part by tyrosine kinase activity.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 is an inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can lead to altered signaling downstream, potentially enhancing C430048L16Rik activity if it is modulated by PI3K/AKT pathways.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$90.00
$349.00
284
(5)

SB203580 is a specific inhibitor of p38 MAP kinase. By inhibiting p38, the compound could redirect cellular signaling to favor the activation of C430048L16Rik if p38 negatively influences C430048L16Rik activity.

D-erythro-Sphingosine-1-phosphate

26993-30-6sc-201383
sc-201383D
sc-201383A
sc-201383B
sc-201383C
1 mg
2 mg
5 mg
10 mg
25 mg
$165.00
$322.00
$570.00
$907.00
$1727.00
7
(1)

S1P is a signaling sphingolipid that activates sphingosine-1-phosphate receptors, leading to various downstream signaling events. If C430048L16Rik is part of these signaling cascades, S1P could enhance its activity by activating these pathways.